Redeye presents its preview for Paxman’s Q1 2026 report, due on May 21.
Redeye retains its positive view of q.beyond even though Q1 came in short of our expectations.
For Q1, we forecast 8% sales growth y/y (+17% FX-adjjusted) and EBIT of SEK -6m (-8m last year).
Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand th...
Earlier today, Waystream announced a five-year framework agreement with GlobalConnect, one of Northe...
Redeye is positive about the large SEK23m order from ClearPoint Neuro, as we believe it provides muc...
Q1 preliminary sales grew 8% yoy to € 22.3m, marking the first quarter with top-line growth since Q1...
Mendus’s Q126 results reflect the execution of its expanded clinical strategy for vididencel, with t...
(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.
BeammWave’s Q1 keeps the commercialisation story alive, but the share is running ahead of hard evide...
Redeye comments on q.beyond’s Q1 report, showing soft gross profit and EBITDA but also a retained gu...
Administer reports Q1 figures on May 13. We expect a slight topline decline alongside improved profi...
Last week, Roche announced the acquisition of PathAI for up to $ 1.
Xbrane delivered a quiet Q1, showing revenue of SEK17.
Redeye updates on Invisio after Q1-results which were lower than expected, albeit partly due to a on...
Ferroamp reported Q1 sales growth of 74% y-o-y, driven by increased deliveries to Aira and Elvy as w...
Redeye provides an update following Corline’s Q1 2026 report.
Catella's Q1 2026 missed Redeye's already-reduced forecast on AUM, fee/AUM and EBIT, and the share f...
Redeye initiates coverage of KDventures, a uniquely VC-style listed investment company focused on bi...
